Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes

Fig. 3

Univariate sensitivity analysis of extending the current program with vaccination of children aged 2–16 years at 50% coverage. The human capital approach values productivity losses of premature influenza deaths until the age of retirement. CS, cost-saving; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; Q-LAIV, quadrivalent live-attenuated influenza vaccine; y, years

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us